
|Videos|July 15, 2022
CAR T-cell therapy in prostate cancer: Early results and ongoing trials
Author(s)Urology Times staff
“We are seeing responses,” says Tanya Dorff, MD.
Advertisement
Tanya Dorff, MD, discusses early results with CAR T-cell therapy in patients with prostate cancer and describes ongoing clinical trials exploring the treatment in this setting. Dorff is a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mark Tyson, MD shares promising BOND-003 results in papillary NMIBC
2
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
3
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
4
Choosing salvage therapy after prostate cancer focal ablation
5

















